Evaluation of the Effect of Low-dose Aspirin on the Prevention of Preterm Delivery in Women with a History of Spontaneous Preterm Delivery

Avaliação do efeito da aspirina em baixa dose na prevenção do parto prematuro em mulheres com história de parto prematuro espontâneo

Masoumeh Mirzamoradi1, Zahra Dehghani1, Pegah Azadi1, Maryam Mohammadi1, Armin Khavandegar2, Mahmood Bakhtiyari3

1 Department of Obstetrics and Gynecology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Sina Trauma and Surgery Research Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
3 Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran


Abstract

Objective Currently, uteroplacental vascular disorders are considered one of the main mechanisms of spontaneous preterm delivery (PTD). Low-dose aspirin is used to prevent pre-eclampsia, which has a similar mechanism; hence, the present study aimed to investigate the effect of low-dose aspirin on the prevention of PTD in women with a history of spontaneous PTD.

Methods The present pilot randomized clinical trial was conducted on 54 pregnant women in the aspirin group (taking 80 mg daily until the 36th week and classic treatment) and 53 patients in the control group (only receiving classic treatment).

Results Forty-three patients (40%) presented before 37 weeks due to symptoms of PTL. Preterm delivery (< 37 weeks) occurred in 28 patients (26%), and there was no significant difference between the aspirin and control groups (10 patients [19%] and 18 patients [34%], respectively; p = 0.069). The time of preterm delivery was early (< 34 weeks) in 6 patients (21%), and its cause was spontaneous labor in 23 patients (82%) which was not significantly different between the two groups (p > 0.05). Out of 40 patients with spontaneous labor, 25 patients (63%) had a PTD, which was significantly lower in the aspirin group than in the control group (9 patients [45%] versus 16 patients [80%], respectively; p = 0.022).

Conclusion The findings of the present study demonstrated that despite the reduction in the incidence of PTD using low-dose aspirin, the reduction rate was not statistically significant. On the other hand, in patients with spontaneous labor prone to PTD, aspirin was effective in reducing the incidence of PTD.
Introduction

Preterm labor (PTL) before the 37th week of gestation is the most common cause of worldwide morbidity and mortality in newborns. The prevalence of PTL in developed and developing countries is 5 and 25%, respectively. Preterm labor is responsible for 75% of all cases of neonatal mortality and for 40% of all cases of neurologic neonatal morbidities. Since currently there is no effective medical treatment for termination of the PTL process, the best and most reasonable solution is to identify women at risk and utilize preventive medical interventions.

Despite an intensive bulk of studies on PTL pathophysiology, there is still much controversy on its mechanism. One of the most acceptable theories is bypassing or early stimulation of "parterition complex cascade", known to be responsible for on-time labor triggering. Besides, labor is believed to be a proinflammatory event. Preterm labor as an overwhelming inflammatory event occurring earlier in the midtrimester has been reported to be followed by an intraamniotic infection in almost 50% of PTL cases.

The most important risk factors for preterm delivery (PTD) are a previous history of PTD, smoking, vaginal bleeding, and preterm premature rupture of the membrane (PPROM). There is a bulk of studies that report that placental uterine ischemia plays a crucial role in spontaneous PTL and women with a PTL history are at a higher risk of cardiovascular disease in the future. These findings indicate that the mechanism of PTL is similar to that of other ischemic placental diseases such as pre-eclampsia. Low-dose aspirin is used to inhibit platelet aggregation and prevent pre-eclampsia.

Due to the similarity between the mechanisms of spontaneous PTL and pre-eclampsia, it has been suggested that low-dose aspirin may also be used to prevent spontaneous PTL. Some studies have performed secondary analyses of data on the effect of low-dose aspirin on the prevention of pre-eclampsia to evaluate the effect of low-dose aspirin on the prevention of PTL. Although some studies have reported the effectiveness of low-dose aspirin in preventing PTL, other studies did not prove it. Moreover, a randomized clinical trial was conducted to compare the effect of low-dose aspirin on the incidence of PTL but its clinical results have not been reported yet. Therefore, it seems that no independent study has been conducted in this field so far, and the results of studies on the effect of low-dose aspirin on the prevention of PTL are secondary analyses in patients with risk factors for pre-eclampsia. Therefore, the present study aimed at evaluating the effect of aspirin on the prevention of PTD in women with a history of preterm delivery.

Methods

The present randomized clinical trial was conducted as a pilot study on pregnant women with a history of PTD who were referred to the Mahdieh and Shohada Tajrish hospitals in Tehran, Iran, in 2019 and 2020. The inclusion criteria consisted of age >18 years old, singleton pregnancy,
Low-dose Aspirin and Preterm Delivery

Mirzamoradi et al.

betamethasone, administration of tocolytic agents and its type, PTD cause, infant need for neonatal intensive care unit (NICU) and duration of stay in NICU were also recorded. Finally, the incidence of PTD (in < 37 weeks) and its time and causes were compared between the two groups. IBM SPSS Statistics for Windows version 25 (IBM Corp., Armonk, NY, USA) was used for data entry and analysis. Qualitative variables were described using frequency and percentage, and quantitative variables were described using the mean and standard deviation (SD) or median and interquartile range (IQR). The chi-squared test, the Fisher Exact test, the independent t-test, and the Mann-Whitney U test were used to analyze the data. The significance level was set as \( p < 0.05 \).

All methods used in the present study are based on the principles of Helsinki Human Studies. Patient information will be kept entirely confidential during and after the study. The study was approved by the ethics committee of Shahid Beheshti University of Medical Sciences (Registration code: IR.SBMU.MSP.REC.1398.528) and was registered in the site of the Iranian registry of clinical trials (www.irct.ir) (Registration code: IRCT20191031045289N1).

**Results**

- **Table 1** compares the two groups, aspirin and control, in terms of the characteristics of the patients. Pessary and cervical cerclage, respectively, were used in 4 patients (4%) and 16 patients (15%), and there was no significant difference between the two groups (\( p > 0.05 \)). Only two stillbirths occurred in the present study, one in the case group and one in the control group. Forty-three patients (40%) presented symptoms of PTL before 37 weeks, which was not significantly different between the aspirin and control groups (21 patients [39%] and 22 patients [42%], respectively; \( p = 0.782 \)). Among them, the cause of referral was spontaneous labor in 40 patients (93%) (20 patients in each group) and PPROM in 3 patients (7%) (1 patient in the aspirin group and 2 patients in the control group). Among all patients, 10 patients (21%) received betamethasone injection was applied in 40 patients (37%), and there was no significant difference between the aspirin group and control group (18 patients [33%] versus 22 patients [42%]; \( p = 0.382 \)). In three patients, betamethasone was not used due to impending delivery or maternal diabetes. In general, tocolytic agents were used in 16 (40%) patients, that is: magnesium sulfate in 8 patients, indomethacin in 7 patients, and nifedipine in 1 patient. There was no significant difference between the aspirin and control groups in terms of the frequency of tocolytic administration (6 patients [11%] versus 10 patients [19%], respectively; \( p = 0.261 \)). Preterm delivery occurred in 28 patients (26%), and there was no significant difference between the aspirin group and the control group (10 patients [19%] versus 18 patients [34%]; \( p = 0.069 \)). The time of PTD was early in 6 patients (21%), and its cause was spontaneous labor in 23 patients (82%), which was not significantly different between the aspirin group and control group (\( p > 0.05 \)). Out of 40 patients with spontaneous labor, despite using methods for preventing PTL, 25 patients (63%) had PTD.
which was significantly lower in the aspirin group than in the control group \( (p = 0.022) \) (\textit{Table 3}).

In 16 patients receiving tocolytic agents, the IQR and median duration of prolongation of pregnancy were 1 to 7 weeks and 3.5 weeks, respectively. The effect of tocolytic factors on the prolongation of pregnancy in the aspirin group was significantly higher than that in the control group (7 weeks versus 2 weeks, respectively; \( p = 0.007 \)). \textit{Table 4} also presents the characteristics of infants.

**Discussion**

In the present study, we aimed to assess the preventive effect of low-dose aspirin on PTL in pregnant women with a history of PTD. Although not being statistically significant, the findings of the present pilot study revealed that low-dose aspirin prescription in women with a history of PTD reduced the incidence of PTD. Moreover, we realized that in patients with a history of spontaneous PTD, receiving low-dose aspirin...
significantly reduced PTD if the patient experienced spontaneous labor in the current pregnancy.

In a study by Hoffman et al. on pregnant women from low- to middle-income countries, low-dose aspirin showed reduced PTD prior to 37 weeks, in addition to decreased perinatal mortality. In contrast, in a study published in 2022 encompassing 608 pregnant women with a history of spontaneous preterm birth, low-dose aspirin did not demonstrate a significant reduction in preterm birth.

### Table 1: Comparison of patient characteristics between the two groups

| Variables                 | Aspirin group (n = 54) | Control group (n = 53) | p-value  
|--------------------------|------------------------|------------------------|----------
| Age (years old)          | Mean ± SD              | 31 ± 5                 | 30 ± 5   | 0.134†  
| Gravity                  |                        | 21 (39%)               | 23 (44%) | 0.891‡  
|                          |                         | 25 (46%)               | 23 (44%) |          
|                          |                         | 8 (15%)                | 7 (12%)  |          
| Abortion history         | None                   | 34 (63%)               | 34 (64%) | 0.701‡  
|                          | 1                      | 9 (17%)                | 12 (23%) |          
|                          | 2                      | 7 (13%)                | 5 (9%)   |          
|                          | ≥3                     | 4 (7%)                 | 2 (4%)   |          
| Children count           | None                   | 9 (17%)                | 11 (21%) | 0.667‡  
|                          | 1                      | 31 (57%)               | 30 (56%) |          
|                          | ≥2                     | 14 (26%)               | 12 (23%) |          
| Dead child history       | No                     | 37 (68%)               | 37 (70%) | 0.609‡  
|                          | Yes                    | 17 (32%)               | 16 (30%) |          
| Previous PTD cause       | Spontaneous labor      | 48 (89%)               | 42 (79%) | 0.172‡  
|                          | PPROM                  | 6 (11%)                | 11 (21%) |          
| Time of previous PTD     | Early (< 34 weeks)     | 31 (57%)               | 28 (53%) | 0.634‡  
|                          | Late (34–37 weeks)     | 23 (43%)               | 25 (47%) |          

Abbreviations: PTD: preterm delivery; PPROM: preterm premature rupture of membrane; SD: standard deviation.
†Independent t test
‡Chi-squared test;

### Table 2: Comparison of preterm delivery characteristics between the two groups

|                         | Aspirin group (n = 10) | Control group (n = 18) | p-value†  
|-------------------------|------------------------|------------------------|----------
| PTD based on fetal age  | Early (< 34 weeks)     | 2 (20%)                | 4 (22%)  | 1.000    
|                         | Late (34–37 weeks)     | 8 (80%)                | 14 (78%) |          
| PTD etiology            | Spontaneous labor      | 7 (70%)                | 16 (89%) | 0.315    
|                         | PPROM                  | 3 (30%)                | 2 (11%)  |          

Abbreviations: PTD: preterm delivery; PPROM: preterm premature rupture of membrane.
†Fisher Exact test;

### Table 3: Comparison of preterm delivery characteristics in patients referred due to spontaneous labor between the two groups

|                                     | Aspirin group (n = 20) | Control group (n = 20) | p-value‡  
|-------------------------------------|------------------------|------------------------|----------
| Betamethasone administration        | 17 (85%)               | 20 (100%)              | 0.231*   
| Tocolytic agents administration     | 6 (30%)                | 8 (40%)                | 0.507**  
| PTD                                 | 9 (45%)                | 16 (80%)               | 0.022**  

Abbreviation: PTD: Preterm delivery.
*Fisher Exact test
**Chi-squared test
the effect of antiplatelet agents on reducing pre-eclampsia. Although our study, an independent study in women at risk for PTL, was associated with a reduced incidence of PTD in the aspirin group, there was no statistically significant difference. On the other hand, the median duration of prolongation of pregnancy was significantly higher in patients receiving tocolytic agents in the aspirin group. However, because the incidence of PTD was significantly lower in the aspirin group in a subgroup of patients who presented with spontaneous labor in the current pregnancy and were at risk for PTD, it may not be significant in all patients due to the small sample size.

No independent study has been conducted to investigate the effect of low-dose aspirin on the prevention of spontaneous PTL, and studies in this field have been the secondary analyses of research conducted on women with risk factors for pre-eclampsia. The latest recommendations of the American Association of Obstetricians and Gynecologists also indicate that currently, due to lack of sufficient evidence, prophylactic administration of low-dose aspirin has not been approved for the prevention of conditions such as PTL and stillbirth, among others, in the absence of risk factors for pre-eclampsia. Hence, as the strength of our study, it was conducted as an independent randomized clinical trial on the effect of low-dose aspirin on controlling PTD due to PTL.

### Table 4 Comparison of neonatal characteristics between the two groups

<table>
<thead>
<tr>
<th></th>
<th>Aspirin group (n = 54)</th>
<th>Control group (n = 53)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newborn sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Girl</td>
<td>30 (56%)</td>
<td>35 (66%)</td>
<td>0.276†</td>
</tr>
<tr>
<td>Boy</td>
<td>24 (44%)</td>
<td>18 (34%)</td>
<td></td>
</tr>
<tr>
<td>Apgar 1st minute</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤6</td>
<td>0 (0%)</td>
<td>1 (2%)</td>
<td>0.482‡</td>
</tr>
<tr>
<td>7–8</td>
<td>6 (11%)</td>
<td>8 (15%)</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>48 (89%)</td>
<td>44 (83%)</td>
<td></td>
</tr>
<tr>
<td>Apgar 5th minute</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤8</td>
<td>0 (0%)</td>
<td>1 (2%)</td>
<td>0.641‡</td>
</tr>
<tr>
<td>9</td>
<td>5 (9%)</td>
<td>6 (11%)</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>49 (91%)</td>
<td>46 (87%)</td>
<td></td>
</tr>
<tr>
<td>NICU admission</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NICU admission cause</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prematurity, RDS or TTN</td>
<td>7 (70%)</td>
<td>16 (94%)</td>
<td>0.128‡</td>
</tr>
<tr>
<td>Others</td>
<td>3 (30%)</td>
<td>1 (6%)</td>
<td></td>
</tr>
<tr>
<td>NICU stay</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1–2 days</td>
<td>4 (40%)</td>
<td>9 (53%)</td>
<td>0.849‡</td>
</tr>
<tr>
<td>&gt; 3 days</td>
<td>6 (60%)</td>
<td>8 (47%)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: NICU, neonatal intensive care unit; RDS: respiratory distress syndrome; TTN: transient neonatal tachypnea
†Fisher Exact test
‡Chi-squared test
spontaneous labor or PPROM. However, our results showed that low-dose aspirin is not effective in preventing spontaneous PTD in women with a previous history of PTD caused due to spontaneous labor or PPROM.

However, the small sample size, which was the most significant limitation of our study, may have provided statistically insignificant results. In addition, due to not using a placebo in our research, there was no blinding. Therefore, it is recommended to conduct extensive multicenter studies with larger sample sizes and utilize a placebo.

Despite our effort to provide a rationale for using low-dose aspirin in PTL, there were some limitations to the present study. The main limiting factor in the present study is the small sample size, eclipsing its representativeness. Further studies are needed to evaluate the effectiveness of low-dose aspirin in larger populations. Besides, as we were concerned about the term "proven therapy" as defined in the Helsinki declaration, we refused to expose patients in the control group to placebo drugs.29,30 Besides, since pregnancy is a very delicate and sensitive issue, most patients would have refused to use a "a not-knowing-what-it-is drug". Recently, there have been some concerns regarding the placebo usage even in the normal population.29,30 Further studies are needed to assess the placebo effect in a larger population of PTL cases.

Conclusion
The findings of the present study showed that despite the reduction in the incidence of PTD using low-dose aspirin, the reduction rate was not statistically significant. On the other hand, in patients with spontaneous labor prone to PTD, aspirin was effective in reducing the incidence of PTD. Therefore, conducting more extensive studies with larger sample sizes may produce significant results.

Contributions
Mirzamoradi M. contributed to the study design and methodology. Dehghani Z. supervised the whole process and modified it. Bakhtiyari M. contributed to manuscript provision, data analysis, and the submission process. Mohammadi M. and Khavandegar A. contributed to the writing and draft editing. All authors have read and approved the manuscript.

Conflict of Interests
The authors have no conflict of interests to declare.

Acknowledgments
We would like to thank all the patients who participated in the present study.

References
5 Bruinsma FJ, Quinn MA. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. BJOG. 2011;118(9):1031–1041
22 Goldenberg RL. The management of preterm labor. Obstet Gynecol. 2002;100(5 Pt 1):1020–1037
29 Tugwell P, Tovey D. In 2021 When Is It Unethical to Use a Placebo in a Clinical Trial? J Clin Epidemiol. 2021;133:A5–A6
30 Elliott DB. The placebo effect: is it unethical to use it or unethical not to? Ophthalmic Physiol Opt. 2016;36(05):513–518